The vagus nerve is the heart’s primary brake — its acetylcholine release at the sinoatrial node is what prevents the heart from racing at its intrinsic rate of approximately 100 beats per minute. But the relationship between vagal activity and cardiac health is not simply “more vagus = better heart.” Excessive vagal discharge causes fainting. Paradoxical vagal effects can trigger atrial fibrillation. Insufficient vagal tone contributes to heart failure progression. The vagus nerve’s cardiac influence is powerful, bidirectional, and clinically significant in ways that extend far beyond the simplified “rest and digest” narrative.
Vasovagal Syncope: The Vagal Faint
Vasovagal syncope is the most common cause of fainting, accounting for approximately 50% of all syncope episodes and affecting roughly one-third of people at least once during their lifetime. Despite being common and usually benign, the mechanism is counterintuitive — it is essentially a malfunction of the body’s cardiovascular feedback loop.
The classic trigger sequence: prolonged standing, pain, emotional distress (blood or needle phobia), or Valsalva strain causes venous blood to pool in the legs and abdomen. The heart compensates by contracting more vigorously against an increasingly empty ventricle. Mechanoreceptors in the ventricular wall detect this vigorous contraction with low volume and misinterpret it as dangerously high blood pressure — the Bezold-Jarisch reflex. These receptors fire vagal afferents to the brainstem, which responds by dramatically increasing vagal efferent output and simultaneously withdrawing sympathetic tone. The result is sudden bradycardia (heart rate dropping by 30-40 bpm or more) combined with vasodilation (blood pressure plummeting). Cerebral perfusion drops below the threshold for consciousness, and the person faints.
The paradox is that the body’s protective reflex — designed to prevent dangerously high blood pressure — fires in the exact opposite situation. The heart is underfilled, not overfilled, but the ventricular mechanoreceptors cannot distinguish between the two. This is why vasovagal syncope often occurs in young, healthy individuals with good cardiovascular reflexes — their reflexes are too responsive, not too weak.
Diagnosis typically involves tilt-table testing, in which the patient is strapped to a table tilted to 60-70 degrees while heart rate and blood pressure are monitored. A positive test reproduces the syncope episode. Management focuses on recognising prodromal symptoms (lightheadedness, warmth, nausea, visual graying), counterpressure manoeuvres (leg crossing, hand gripping, squatting) to abort the faint, adequate hydration, and in recurrent cases, medications such as midodrine or fludrocortisone. Pacemaker implantation is reserved for severe, recurrent vasovagal syncope with documented prolonged asystole (heart pauses exceeding 6 seconds during monitoring).
Vagal Atrial Fibrillation
Atrial fibrillation (AF) — the most common sustained cardiac arrhythmia, affecting approximately 37 million people worldwide — has a vagally-mediated subtype that is under-recognised. Vagal AF occurs when increased parasympathetic tone shortens the atrial refractory period (the recovery time between electrical activations) heterogeneously across the atrial tissue. This heterogeneity creates the conditions for re-entrant electrical circuits — waves of activation that loop back on themselves, producing the chaotic atrial electrical activity that defines fibrillation.
The clinical profile of vagal AF is distinct: episodes typically occur at rest, during sleep, or after large meals (when vagal output is highest). It predominantly affects younger men (under 60) with structurally normal hearts, often athletes or individuals with high baseline vagal tone. This contrasts with adrenergic AF, which is triggered by exercise, emotional stress, or stimulant use and occurs against a background of sympathetic activation.
The distinction matters for treatment. Beta-blockers, the standard first-line rate control for AF, work by blocking sympathetic input to the heart — but in vagal AF, sympathetic activity is not the problem. Beta-blockers can actually worsen vagal AF by removing the sympathetic counterbalance to vagal effects, leading to more frequent or prolonged episodes. Vagal AF often responds better to disopyramide (an antiarrhythmic with anticholinergic properties), flecainide, or lifestyle modifications that reduce extreme vagal surges (avoiding very large meals, not lying flat immediately after eating, and reducing alcohol intake — a potent vagal AF trigger).
Your local vagus nerve experts
Find a vagus nerve practitioner near you
Our directory lists 2,685 practitioners across the US, from polyvagal-informed therapists to HRV biofeedback clinics.
Or browse by approach
- HRV biofeedback
- Polyvagal-informed therapy
- Somatic therapy
- Craniosacral therapy
- Breathwork
- Insomnia therapy (CBT-I)
The directory covers the United States for now. Listings come from practitioners’ own websites and are not endorsements or medical advice. Browse the full directory.
Bradycardia: When Vagal Tone Is Too High
Resting heart rates below 60 bpm are classified as bradycardia, but context determines whether this is pathological or physiological. Endurance athletes routinely have resting heart rates of 40-50 bpm due to exercise-induced vagal enhancement — a beneficial adaptation that reflects efficient cardiac function and high stroke volume. These individuals are asymptomatic and require no treatment.
Pathological vagal bradycardia occurs in several contexts. Carotid sinus hypersensitivity — an exaggerated vagal response to pressure on the carotid sinus in the neck — can cause bradycardia and syncope triggered by tight collars, head turning, or shaving. This condition is most common in older adults with atherosclerotic carotid arteries and is diagnosed by carotid sinus massage under monitored conditions (producing a heart rate pause exceeding 3 seconds or a systolic blood pressure drop exceeding 50 mmHg).
Sick sinus syndrome with vagal predominance involves intrinsic sinoatrial node dysfunction compounded by excessive vagal inhibition, producing alternating bradycardia and tachycardia (tachy-brady syndrome). Drug-induced vagal bradycardia can occur with beta-blockers, calcium channel blockers (verapamil, diltiazem), digoxin, and cholinesterase inhibitors (donepezil, rivastigmine) — medications that either enhance vagal effects or reduce the heart’s ability to compensate for them. Pacemaker implantation is indicated when symptomatic bradycardia (dizziness, syncope, exercise intolerance, heart failure symptoms) cannot be managed by adjusting or discontinuing the causative medication.
POTS: When Vagal Tone Is Too Low
Postural orthostatic tachycardia syndrome (POTS) represents the opposite end of the vagal cardiac spectrum — insufficient vagal braking rather than excess. When a healthy person stands, blood pools in the legs due to gravity, and the baroreceptor reflex rapidly increases heart rate (via sympathetic activation) and constricts blood vessels (via both sympathetic and vagal pathways) to maintain cerebral perfusion. In POTS, this compensatory mechanism is impaired — heart rate increases by 30 bpm or more (or exceeds 120 bpm) within 10 minutes of standing, without the corresponding blood pressure drop that defines orthostatic hypotension.
Multiple subtypes of POTS exist, but reduced cardiac vagal tone — measurable as decreased HF-HRV — is a consistent finding across most of them. The vagus nerve normally provides a continuous “vagal brake” that modulates heart rate beat-to-beat. When this brake is weakened (through deconditioning, autoimmune damage to autonomic ganglia, post-viral vagal neuropathy, or other mechanisms), the heart rate becomes disproportionately responsive to sympathetic input, producing the characteristic tachycardia on standing.
Post-COVID POTS has brought enormous attention to this condition since 2020. Vagal neuropathy — directly or immunologically mediated damage to the vagus nerve following SARS-CoV-2 infection — is one of several proposed mechanisms. Autonomic testing in post-COVID POTS patients frequently shows reduced cardiovagal function on deep breathing and Valsalva testing, consistent with vagal impairment. Treatment targets both the tachycardia (low-dose beta-blockers, ivabradine) and the underlying vagal deconditioning (graded exercise programmes, salt and fluid loading, compression garments).
Vagus Nerve Stimulation for Heart Failure
Heart failure is characterised by a progressive imbalance between sympathetic overdrive (which pushes the failing heart harder) and vagal withdrawal (which removes the protective braking and anti-inflammatory effects). As heart failure advances, sympathetic activity rises and vagal tone falls — a combination that accelerates cardiac deterioration through increased heart rate, pro-inflammatory cytokine release, and impaired baroreceptor function.
This pathophysiology made VNS an attractive therapeutic target. The ANTHEM-HF trial (Autonomic Neural Regulation Therapy to Enhance Myocardial Function in Heart Failure) implanted vagus nerve stimulators in patients with reduced ejection fraction heart failure and demonstrated improvements in left ventricular ejection fraction, functional capacity, and quality of life at 6 and 12 months. The larger INOVATE-HF trial, however, failed to show a mortality or hospitalisation benefit, dampening initial enthusiasm.
Subsequent analysis suggested that stimulation parameters — not the concept itself — may have been the issue. INOVATE-HF used lower stimulation intensities and different electrode placements than ANTHEM-HF. The ongoing ANTHEM-HFrEF programme and newer closed-loop VNS systems (which adjust stimulation in real-time based on cardiac autonomic markers) represent a second generation of cardiac VNS research. Additionally, the cholinergic anti-inflammatory pathway — in which vagal efferents to the spleen suppress TNF-alpha and other pro-inflammatory cytokines — may contribute to VNS benefits in heart failure, given that chronic systemic inflammation is a driver of cardiac remodelling and progression.
Protecting Cardiac Vagal Tone
For most people, the practical cardiac concern is not too much vagal activity but too little. Low resting vagal tone — reflected by low HRV — is one of the strongest independent predictors of adverse cardiac outcomes, including post-myocardial infarction mortality, sudden cardiac death, and heart failure progression. Interventions that increase vagal tone offer genuine cardioprotection: regular aerobic exercise (the single most effective vagal tone enhancer), slow-paced breathing at resonance frequency (~6 breaths per minute), and sustained weight loss in obese individuals have all demonstrated HRV improvements in randomised trials.
The key insight is that the vagus nerve’s cardiac role is not static — it is a dynamic, regulatable system. Both excess and deficiency produce pathology, but the modern lifestyle pattern of chronic stress, sedentary behaviour, and poor sleep pushes most people toward vagal insufficiency. Recognising the specific cardiac conditions associated with vagal dysfunction — from the benign but alarming vasovagal faint to the progressive vagal withdrawal of heart failure — allows for targeted prevention and treatment rather than a generic “stimulate the vagus” approach.
The vagus nerve does more for your heart than any other single nerve in the body — but its effects can be protective or pathological depending on context. Understanding the specific cardiac pathways gives you the knowledge to recognise symptoms, ask better questions of your doctor, and take meaningful steps toward cardiovascular resilience. My Vagus Nerve & Me covers the full cardiac connection, from heart rate variability to arrhythmia mechanisms to the latest in vagal therapies. Get My Vagus Nerve & Me eBook and learn to work with your heart’s most powerful regulator.
